National

Covid-19: The daily dose (June 15, 2021)

Mumbai | Updated on June 15, 2021

We curate for you all the Covid-19-related developments and stories of the day worth reading

# As child vaccines become a point of discussion, Bharat Biotech’s Covaxin undertakes trials for paediatric doses.

https://www.thehindubusinessline.com/news/covaxin-trials-start-on-2-18-age-set-at-six-cities/article34815711.ece?homepage=true

# And more to add to the arsenal, now Novavax claims efficacy against variants. And that injects a shot of good news into India’s Covid-prevention programme.

https://www.thehindubusinessline.com/companies/vaccine-shows-93-efficacy-against-variants-novavax/article34815003.ece

# Capillary Leak syndrome: The European regulator EMA asks for additional side-effect labelling on the AZ-Oxford vaccine. Point to note, this is the vaccine that is being rolled out in India, made here by Serum Institute.

# Two Indians are now on CEPI’s scientific advisory board.

https://www.thehindubusinessline.com/news/science/two-indians-selected-to-cepis-scientific-advisory-committee/article34810329.ece

# One dose will do? Well, a local study explores the option being touted by experts in India and overseas.

https://www.thehindubusinessline.com/news/science/one-dose-enough-for-the-covid-hit-population-aig-study/article34814097.ece

# A start-up from Pune comes up with 3D-printed masks. The need for them will continue for sometime, despite the vaccination drive.

https://www.thehindubusinessline.com/news/science/pune-start-up-thincr-develops-3d-printed-masks-with-antiviral-properties/article34810570.ece

# And more oxygen plants are being set up across the country. The second wave brought home the distressing message of shortages, never to be repeated.

https://www.thehindubusinessline.com/news/science/about-850-oxygen-plants-being-set-up-across-the-country-drdo-chief/article34813420.ece

(eom)

Published on June 15, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor